Enveric Biosciences (NASDAQ:ENVB) Stock, Quote.Headers.trade-ideas

Enveric Biosciences

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.

Headquarters_Rahway-Site-Entrance_HI

News

Intraday Update

Markets

Movers

Trading Ideas

AMKR

ATPC

BIMI

BLMZ

CALC

CLDX

CNSP

CRWD

CVLT

EKSO

ENVB

FFIV

HAYW

HLIT

IMNN

INVO

ISPO

JBLU

JTAI

LSCC

LUMN

MBIN

NIPG

NVAX

ONEW

PCSA

PHAR

PYPL

RGEN

RMBS

SMRT

TLRY

TRNS

TWOU

VBIV

VRNS

VSEE

Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

xr:d:DAFgpVtycPU:2,j:3089375048,t:23042013

Pre-Market Outlook

SERV

TROO

Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket

Enveric drug for mental health disorders

Cannabis

Psychedelics

Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally

Enveric Biosciences Inc

Red Cat Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.08) by 112.5 percent. This is a 54.55 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $2.78 million which missed the analyst consensus estimate of $3.85 million by 27.88 percent. This is a 58.84 percent increase over sales of $1.75 million the same period last year.

Earnings

Earnings Misses

RCAT

Red Cat Holdings Q1 EPS $(0.17) Misses $(0.08) Estimate, Sales $2.78M Miss $3.85M Estimate

WIIM

EDUC

Educational Development shares are trading higher after the company announced the sale and leaseback agreement of the headquarters and warehouse facility.

Collective Mining Extends Apollo System Southwest, Reaches Depths Over 1,000 Meters With High-Grade Intersections, Including 39.95 Metres At 4.42 g/t Gold Equivalent, As Part Of 2024 Drill Program In Colombia

Educational Development Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDUC#NASDAQ">EDUC</a>) ("EDC", the "Company" or "Seller") (<a href="https://api.newsfilecorp.com/redirect/gON1msVJkO">http://www.edcpub.com</a>) today announced that on September 19, 2024, it executed a Commercial Real Estate Contract ("Contract") with Partner Holdings or ("Buyer") for the sale of the Company's headquarters and distribution warehouse located at 5400-5402 South 122nd East Avenue, Tulsa, Oklahoma 74146 (the "Hilti Complex").
The agreed upon sale price of the Hilti Complex per the executed Contract totaled $38,250,000 less fees, commissions and closing costs. The proceeds from the sale will be utilized to pay off the Term Loans and Revolving Loan outstanding in the Credit Agreement with the Company's Bank. At closing, EDC will assign the existing Hilti tenant lease to the Buyer and will execute a separate Triple-Net Lease (the "Lease") for its occupied space in the Hilti Complex. The sale agreement does not include the excess land parcel adjacent to the Hilti Complex which will remain under the ownership of EDC.

Asset Sales

Educational Development Corporation Announces Sale And Leaseback Agreement Of Headquarters and Warehouse Facility; The Agreed Upon Sale Price Of The Hilti Complex Per The Executed Contract Totaled $38.25M Less Fees, Commissions And Closing Costs

<h3 class="wp-block-heading">Thousands Are Buying Weed In North Carolina's Only Weed Shop</h3>
Cannabis sales are booming in North Carolina's only legal store selling recreational marijuana. Great Smoky, located on the 57,000-acre Qualla Boundary of the Eastern Band of Cherokee Indians (EBCI,) has been serving all adults 21 and older for a couple of weeks.
The shop at 91 Bingo Loop Road in Cherokee, Swain County, has been selling recreational marijuana as of Saturday, Sept. 7, only to see thousands of customers making cannabis purchases, <a href="https://www.marijuanamoment.net/thousands-flock-to-tribal-marijuana-store-in-north-carolina-where-cannabis-is-otherwise-illegal-for-launch-of-adult-use-sales/">reported</a> Marijuana Moment.
Forrest Parker, general manager for Qualla Enterprises, which operates Great Smoky Cannabis Co., <a href="https://theonefeather.com/2024/09/07/cherokee-begins-sales-of-adult-use-21-cannabis-for-all/">told</a> Cherokee One Feather it's "validating" to see people standing in line to get their cannabis products.
<h3 class="wp-block-heading">Four News Cannabis Stores Open In Florida Amid Marijuana Legalization Debate</h3>
Meanwhile, in Florida, medical cannabis giant Trulieve Cannabis Corp. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TRUL#CSE">TRUL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>) revealed that it will be hosting grand opening celebrations at two new stores on Friday, Sept. 27.
Trulieve Lake Worth Hypoluxo is located at 4660 Hypoluxo Road; Trulieve Hudson at 11909 State Road 52. Both locations will carry a variety of products including Trulieve&#8217;s portfolio of in-house brands such as Alchemy, Co2lors, Cultivar Collection, Modern Flower, Momenta, Muse, Roll One, Sweet Talk, and Trekkers. 
Customers will also have access to the company's partner brands: Alien Labs, Bellamy Brothers, Binske, Black Tuna, Blue River, Connected Cannabis, DeLisioso, Khalifa Kush, Love&#8217;s Oven, Miami Mango, O.pen, Seed Junky and Sunshine Cannabis.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23154706/ccc-oct-24-banner__1_-35.gif" alt="" class="wp-image-561862" /></a></figure>
RISE Dispensaries, a cannabis retail chain owned by Green Thumb Industries Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GTII#CSE">GTII</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>) opened its newest location, RISE Jacksonville, on Friday, Sept. 13. Located at 9421 Baymeadows Road, the dispensary marked the 20th RISE location in the Sunshine State and the 98th nationwide.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out</li>
</ul>
Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTCQX">VRNOF</a>) kicked off sales at MÜV Melbourne and MÜV Okeechobee on Friday, Sept. 13, raising its retail footprint to 79 Florida dispensaries and 152 retail locations nationwide. MÜV Melbourne, located at 7660 N Wickham Road, and MÜV Okeechobee, located at 510 NE Park Street feature online menus for effortless browsing of their extensive, award-winning product selection, including the company's signature Verano Reserve, MÜV and Sweet Supply flower, Encore edibles, On the Rocks concentrates and extracts, and (the) Essence and Savvy flower and extracts, spanning an extensive array of options for patients.
Both Trulieve and Verano are active supporters of the Smart and Safe Florida campaign advocating for the passage of the Amendment 3 ballot initiative to legalize adult-use cannabis statewide.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40923340/trump-says-yes-to-legal-cannabis-in-florida-but-hometown-palm-beach-says-no-thanks-to-weed-shops">Trump Says Yes To Legal Cannabis In Florida, But Hometown Palm Beach Says No Thanks To Weed Shops</a>
<h3 class="wp-block-heading">New York's Cannabis Dispensary Tour Amid New Store Openings</h3>
In New York, Democratic Assembly member John Zaccaro and cannabis fin-tech company Dutchie visited three prominent cannabis dispensaries in the Bronx earlier this month. The tour highlighted the role of these businesses in the community alongside ongoing efforts to combat the illicit market.
Florida-based medical cannabis company The Flowery recently announced the opening of its newest store in the neighborhood of Forest Hills, Queens. The grand opening event at a new store at&nbsp;63-54 108th Street in Forest Hills, New York, follows the launch of the company's first New York location in Staten Island. The store features a direct-to-consumer (DTC) delivery program.
<h3 class="wp-block-heading">New Cannabis Stores In Five States</h3>
In the Golden State, cannabis retail brand Solful will open its third dispensary location in Healdsburg on Oct.11. Solful already boasts award-winning dispensaries in San Francisco and Sebastopol,
Located at 465 Healdsburg Ave in Healdsburg, the new store will offer locally sourced cannabis products, featuring 40 cannabis varieties from local farms.
International cannabis and lifestyle brand Cookies held a ribbon-cutting ceremony on Friday, Sept. 20 at its new medical marijuana dispensary in Louisiana in partnership with Capitol Wellness Solutions. Cookies by Capitol Wellness is a 4,800 square feet store and it offers a wide variety of Cookies products and merchandise such as flower, metered-dose inhalers, extracts, edibles, tinctures and creams.
Cannabis dispensary Sweetspot Farms at 139 Pearl St in Essex Junction, Vermont is now open to cannabis customers. The new store has a strong focus on consumer education and service.
High Haven Cannabis held a grand opening event at a retail dispensary in Elgin, Illinois, on Saturday, Sept. 21.
Vertically-integrated cannabis company Ascend Wellness Holdings, Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#CSE">AAWH</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTCQX">AAWH</a>) opened its fifth medical dispensary in Pennsylvania, located in Whitehall. The expansion marks the company's 39th location across its seven-state footprint.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40150356/heres-where-to-buy-legal-weed-new-yorks-cannabis-market-expands-other-states-are-keeping-up">Here&#8217;s Where To Buy Legal Weed: New York&#8217;s Cannabis Market Expands, Other States Are Keeping Up</a></li>
</ul>

Entrepreneurship

Retail Sales

AAWH

CSE:AAWH

CSE:GTII

CSE:TRUL

GTBIF

GTII

TCNNF

TRUL

VRNOF

Cannabis Sales Bloom In First North Carolina Weed Store, Marijuana Footprint In Florida Grows As Rec Legalization Looms, And More Store Openings

High-rolling investors have positioned themselves bullish on Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GOLD often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Barrick Gold. This is not a typical pattern.
The sentiment among these major traders is split, with 77% bullish and 22% bearish. Among all the options we identified, there was one put, amounting to $25,000, and 8 calls, totaling $499,210.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $25.0 for Barrick Gold, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Barrick Gold stands at 15589.33, with a total volume reaching 5,926.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Barrick Gold, situated within the strike price corridor from $10.0 to $25.0, throughout the last 30 days.
<h3>Barrick Gold 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727121688_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.75</td>
<td>$10.75</td>
<td>$10.75</td>
<td>$10.00</td>
<td>$161.2K</td>
<td>5.5K</td>
<td>300</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$7.25</td>
<td>$7.25</td>
<td>$7.25</td>
<td>$15.00</td>
<td>$78.3K</td>
<td>458</td>
<td>108</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.8</td>
<td>$10.7</td>
<td>$10.77</td>
<td>$10.00</td>
<td>$53.8K</td>
<td>5.5K</td>
<td>50</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.75</td>
<td>$10.65</td>
<td>$10.75</td>
<td>$10.00</td>
<td>$53.7K</td>
<td>5.5K</td>
<td>150</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.49</td>
<td>$0.48</td>
<td>$0.48</td>
<td>$23.00</td>
<td>$48.1K</td>
<td>2.2K</td>
<td>1.9K</td>
</tr>
</tbody>
</table>

<h3>About Barrick Gold</h3>
Based in Toronto, Barrick Gold is one of the world's largest gold miners. In 2023, the firm produced nearly 4.1 million attributable ounces of gold and about 420 million pounds of copper. At year-end 2023, Barrick had about two decades of gold reserves along with significant copper reserves. After buying Randgold in 2019 and combining its Nevada mines in a joint venture with competitor Newmont later that year, it operates mines in 19 countries in the Americas, Africa, the Middle East, and Asia. The company also has growing copper exposure. Its potential Reko Diq project in Pakistan, if developed, could double copper production by the end of the decade.
Having examined the options trading patterns of Barrick Gold, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Barrick Gold's Current Market Status</h3>
<ul>
<li>With a trading volume of 16,896,666, the price of GOLD is down by -1.35%, reaching $20.11.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 38 days from now.</li>
</ul>
<h3>Expert Opinions on Barrick Gold</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $24.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Argus Research has elevated its stance to Buy, setting a new price target at $24. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Barrick Gold with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

GOLD

Market Whales and Their Recent Bets on GOLD Options

Investors with a lot of money to spend have taken a bullish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 44%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $239,254, and 4 are calls, for a total amount of $843,215.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $270.0 to $290.0 for Danaher during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Danaher's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Danaher's significant trades, within a strike price range of $270.0 to $290.0, over the past month.
<h3>Danaher Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727121683_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$18.3</td>
<td>$17.9</td>
<td>$18.3</td>
<td>$270.00</td>
<td>$549.0K</td>
<td>1.3K</td>
<td style="text-align: right;">305</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.1</td>
<td>$4.9</td>
<td>$4.9</td>
<td>$275.00</td>
<td>$169.5K</td>
<td>0</td>
<td style="text-align: right;">658</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$275.00</td>
<td>$67.5K</td>
<td>0</td>
<td style="text-align: right;">275</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$275.00</td>
<td>$57.1K</td>
<td>0</td>
<td style="text-align: right;">123</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$19.3</td>
<td>$18.7</td>
<td>$19.09</td>
<td>$290.00</td>
<td>$49.7K</td>
<td>89</td>
<td style="text-align: right;">26</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>With a volume of 1,107,680, the price of DHR is up 0.37% at $273.65. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 29 days.</li>
</ul>
<h3>What Analysts Are Saying About Danaher</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $290.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has revised its rating downward to Equal-Weight, adjusting the price target to $280. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $300. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Danaher options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Danaher Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MDT, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Medtronic.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $30,528, and 9, calls, for a total amount of $634,635.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $82.5 and $97.5 for Medtronic, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Medtronic's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Medtronic's whale activity within a strike price range from $82.5 to $97.5 in the last 30 days. 
<h3>Medtronic Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727121678_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.2</td>
<td>$1.19</td>
<td>$1.19</td>
<td>$90.00</td>
<td>$143.3K</td>
<td>7.6K</td>
<td>1.7K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.16</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$92.50</td>
<td>$86.9K</td>
<td>592</td>
<td>1.6K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.19</td>
<td>$2.13</td>
<td>$2.13</td>
<td>$92.50</td>
<td>$63.9K</td>
<td>592</td>
<td>960</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.19</td>
<td>$2.13</td>
<td>$2.13</td>
<td>$92.50</td>
<td>$63.9K</td>
<td>592</td>
<td>660</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.2</td>
<td>$2.11</td>
<td>$2.11</td>
<td>$92.50</td>
<td>$63.3K</td>
<td>592</td>
<td>60</td>
</tr>
</tbody>
</table>

<h3>About Medtronic</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
After a thorough review of the options trading surrounding Medtronic, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Medtronic's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,862,431, with MDT's price up by 0.74%, positioned at $90.0.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 57 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Medtronic, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Medtronic Unusual Options Activity For September 23

In the last three months, 23 analysts have published ratings on Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">15</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Dollar Gen, presenting an average target of $116.09, a high estimate of $170.00, and a low estimate of $85.00. Experiencing a 21.1% decline, the current average is now lower than the previous average price target of $147.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1727121676_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Dollar Gen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$102.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$90.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Koji Ikeda</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$95.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$97.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$90.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$122.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$103.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$94.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Bobby Griffin</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$100.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$90.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Chuck Grom</td>
<td>Gordon Haskett</td>
<td>Announces</td>
<td>Hold</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$130.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$130.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Chris Graja</td>
<td>Argus Research</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$148.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$140.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dollar Gen. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Dollar Gen compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Dollar Gen's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Dollar Gen's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dollar Gen analyst ratings.</a>
<h2>All You Need to Know About Dollar Gen</h2>
With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.
<h3>A Deep Dive into Dollar Gen's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Dollar Gen's revenue growth over a period of 3 months has been noteworthy. As of 31 July, 2024, the company achieved a revenue growth rate of approximately 4.23%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Dollar Gen's net margin is impressive, surpassing industry averages. With a net margin of 3.66%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dollar Gen's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.25%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Dollar Gen's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.19%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Dollar Gen's debt-to-equity ratio stands notably higher than the industry average, reaching 2.51. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Dollar Gen: Insights From 23 Financial Analysts

Ratings for Floor &amp; Decor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Floor &amp; Decor Hldgs, presenting an average target of $103.87, a high estimate of $127.00, and a low estimate of $80.00. Highlighting a 10.62% decrease, the current average has fallen from the previous average price target of $116.21. 
<img src="https://www.benzinga.com/files/images/story/2024/1727121663_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Floor &amp; Decor Hldgs among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Sell</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Steven Forbes</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Justin Kleber</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Max Rakhlenko</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Justin Kleber</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$127.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Floor &amp; Decor Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Floor &amp; Decor Hldgs compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Floor &amp; Decor Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Floor &amp; Decor Hldgs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FND/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Floor &amp; Decor Hldgs analyst ratings.</a>
<h2>All You Need to Know About Floor &amp; Decor Hldgs</h2>
Floor &amp; Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site.
<h3>Floor &amp; Decor Hldgs: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Floor &amp; Decor Hldgs faced challenges, resulting in a decline of approximately -0.24% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Floor &amp; Decor Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.0%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Floor &amp; Decor Hldgs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.81%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Floor &amp; Decor Hldgs's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Floor &amp; Decor Hldgs's debt-to-equity ratio is below the industry average at 0.83, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Floor & Decor Hldgs Stock: Analyst Perspectives (15 Ratings)

Across the recent three months, 21 analysts have shared their insights on Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Dollar Tree and provided 12-month price targets. The average target is $94.33, accompanied by a high estimate of $155.00 and a low estimate of $64.00. This current average has decreased by 31.25% from the previous average price target of $137.21. 
<img src="https://www.benzinga.com/files/images/story/2024/1727121651_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Dollar Tree's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$64.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$68.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$81.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$79.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$78.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Hold</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$148.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$112.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dollar Tree. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Dollar Tree compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Dollar Tree's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dollar Tree's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DLTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dollar Tree analyst ratings.</a>
<h2>Discovering Dollar Tree: A Closer Look</h2>
Dollar Tree operates discount stores across the United States and Canada, with over 8,600 shops under its namesake banner and nearly 7,800 under Family Dollar. About 47% of Dollar Tree's sales in fiscal 2023 were composed of consumables (including food, health and beauty, and cleaning products), around 45% from variety items (including toys and homewares), and over 5% from seasonal items. The Dollar Tree banner sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. Conversely, Family Dollar primarily sells consumable merchandise (80% of the banner's sales) at prices below $10. About two-thirds of Family Dollar's stores are located in urban and suburban markets, with the remaining one-third located in rural areas.
<h3>Dollar Tree's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Dollar Tree's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.73% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 1.79%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Dollar Tree's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.8%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Dollar Tree's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.59%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Dollar Tree's debt-to-equity ratio is below the industry average at 1.46, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DLTR

Unveiling 21 Analyst Insights On Dollar Tree

EMCOR Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eme#NYSE">EME</a>) shares reached a new 52-week high of $437.10 on Friday. The stock pulled back to end the trading session at $435.60, gaining 1.3% that day. Impressively, the stock marked a 9.9% surge in the past five days.
The move came in after the most awaited interest rate cut news, which boosted the overall market sentiments. On Wednesday, the Federal Reserve announced an interest rate cut by 50 cents to a range of 4.75% to 5%. Reduced interest rates can have a highly supportive effect on infrastructure stocks, benefiting from cheaper financing, increased government and private sector investment, higher appeal for dividend-seeking investors, and potential growth in related sectors like real estate.
In the year-to-date period (YTD), the stock surged more than 104%, handily outpacing the Zacks Building Products - Heavy Construction industry&#39;s 79.9% growth, the broader Construction sector&#39;s 22.6% rise and the S&amp;P 500&#39;s 19.6% increase. Investors looking for momentum stock may dig into EME right now.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/b5/78846.jpg?v=176645747" />
Image Source: Zacks Investment Research
EMCOR, known for its strategic focus and diverse offerings, has seen significant growth in recent years amid a competitive landscape of non-residential services.
Substantiating the above-mentioned optimism, the 50-day SMA continues to read higher than the 200-day SMA, signaling a bullish trend. This technical strength underscores positive market sentiment and confidence in EMCOR&#39;s financial health and prospects.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/24/78848.jpg?v=784714474" />
Image Source: Zacks Investment Research
Other stocks from the same industry that touched a 52-week high on Sept. 20 are Dycom Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dy#NYSE">DY</a>), MasTec, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mtz#NYSE">MTZ</a>) and Great Lakes Dredge &amp; Dock (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gldd#NASDAQ">GLDD</a>). These stocks surged 72.2%, 67.1% and 40.7%, respectively, in YTD.
Let&#39;s delve deeper into the factors substantiating this Fortune 500 company&#39;s resilience, which currently captures around $17 billion of total market share.
<h2>Solid Diversified Business</h2>
EMCOR has established itself as a leader in mechanical and electrical construction, industrial infrastructure, and building services. Its focus on these specialized sectors has positioned the company to dominate markets requiring expert solutions.
A key strength of EME is its investment in Virtual Design and Construction&nbsp;technologies, including Building Information Modeling (BIM), which helps the company design and coordinate complex projects. This technology also enhances its prefabrication processes, enabling customized fabrication for electrical, sheet metal, fire sprinkler, and piping systems, thus improving efficiency and competitiveness.
With the growing emphasis on energy efficiency and sustainability, EMCOR is well-positioned to benefit from the increased demand for HVAC and lighting retrofits, as well as building automation services. The Mechanical Services division, which generates nearly 65% of EMCOR&#39;s total revenues, plays a crucial role in meeting this demand and driving the company&#39;s success.
The company also expands in high-growth sectors and geographies via acquisitions. In the first half of 2024, EMCOR acquired four companies. The acquired companies are set to strengthen their Mechanical Construction, Building Services and Industrial Services segments, positioning them well for future growth.
<h2>EME&#39;s High RPO Levels May Boost Growth</h2>
EMCOR reported remaining performance obligations (RPOs) of $9 billion at end of second-quarter 2024, reflecting an 8.6% year-over-year increase. This near-record RPO level highlights a robust pipeline of future projects, particularly in sectors like data centers, high-tech manufacturing, healthcare, and water/wastewater.
RPOs in the network and communications sector, which includes data centers, reached a record $1.7 billion, marking 40% year-over-year growth. This surge emphasizes EMCOR&#39;s strong position in the expanding data center market, indicating significant future revenue potential.
<h2>Strong Cash Flow</h2>
The company generated $412 million in operating cash flow in the first six months of 2024, almost double the amount from the prior-year period. This strong cash flow supports the company&#39;s ability to fund growth initiatives, pursue acquisitions, and return capital to shareholders.
EMCOR invests in expanding prefabrication and VDC technologies, including BIM, automation, and robotics, while also engaging in various M&amp;A activities. Additionally, the company provides impressive returns to its stockholders through share repurchases and dividends. In 2024, EMCOR increased its quarterly dividend by 39% to 25 cents.
<h2>Obstacles Hindering EME&#39;s Growth Trajectory</h2>
EMCOR has faced difficulties in the commercial real estate market due to reduced demand and the completion of several projects. The U.S. and U.K. site-based services businesses, particularly in the U.S. Building Services segment, have experienced revenue setbacks, mainly due to the non-renewal of certain contracts in the last reported quarter.
In addition to sector-specific challenges, EMCOR is exposed to risks from fluctuating global energy markets and supply-chain disruptions. These factors could limit infrastructure investments and increase project costs, creating obstacles to the company&#39;s growth prospects.
<h2>Valuation, Return &amp; Growth Trend</h2>
EMCOR&#39;s shares are currently overvalued marginally. Its forward 12-month price-to-earnings (P/E) ratio of 22.27 is above its five-year median of 16.23 and the industry&#39;s average of 21.66 currently.
EME provides solid investment returns compared to the industry&#39;s average, as reflected by its current trailing 12-month Return on Equity of 32.7%. This indicates the company efficiently uses its shareholders&#39; funds.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/2b/78847.jpg?v=1312124596" />
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for EME&#39;s earnings has moved up in the past 60 days, indicating analysts are showing confidence in the stock. Over the last 60 days, forecasts for 2024 and 2025 have increased to $19.50 (from $16.10) and $19.59 (from $17.41), respectively.
<h2>Final Thoughts</h2>
EMCOR&#39;s focus on advanced technologies and sustainability, robust capital allocation strategy, and strong financial performance make it a must-buy for investors looking for good long-term gain. Also, Fed&#39;s rate cut is likely to bolster the infrastructure market by lowering borrowing costs, enhancing project viability, encouraging investment, and stimulating economic growth.
However, some industry headwinds and a high valuation depict a risk to the sustainability of its current price if the company&#39;s future performance does not meet investors&#39; expectations.
We believe its impressive business structure, as well as economic rebound, will help the company generate higher earnings in coming quarters. Additionally, solid return and future earnings expectations reinforce its Zacks Rank #1 (Strong Buy) rating, making EMCOR an attractive addition to investors&#39; portfolio at present.
<a href="https://www.zacks.com/stock/news/2340075/emcor-hits-52-week-high-is-the-stock-still-worth-buying?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2340075">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Dividends

Financing

Offerings

Small Cap

GLDD

EMCOR Hits 52-Week High: Is the Stock Still Worth Buying?

Ratings for Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $210.33, a high estimate of $224.00, and a low estimate of $194.00. Marking an increase of 1.69%, the current average surpasses the previous average price target of $206.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1727121641_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Assurant. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Nadel</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$224.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Tommy McJoynt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$194.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>John Nadel</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Grace Carter</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$222.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Assurant. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Assurant compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Assurant's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Assurant's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AIZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Assurant analyst ratings.</a>
<h2>Discovering Assurant: A Closer Look</h2>
Assurant Inc offers a range of property-casualty, health, employee benefit, and warranty insurance to a client base made up of individuals and institutions. Its segments are Global Housing, Global lifestyle, Corporate and Other. Global Housing provides lender-placed homeowners insurance, lender-placed manufactured housing insurance and lender-placed flood insurance; renters insurance and related products; and voluntary manufactured housing insurance, voluntary homeowners insurance and other specialty products. Global Lifestyle, the key revenue-generating segment, provides mobile device solutions and extended service products and related services for mobile devices, consumer electronics and appliances; vehicle protection; and credit protection and other insurance products.
<h3>Assurant's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Assurant's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 7.08%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Assurant's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 6.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Assurant's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.8% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Assurant's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.56%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Assurant's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.42, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Assurant: Insights From 6 Financial Analysts

Analysts' ratings for Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Expedia Group, presenting an average target of $142.93, a high estimate of $180.00, and a low estimate of $130.00. Witnessing a positive shift, the current average has risen by 0.17% from the previous average price target of $142.69.
<img src="https://www.benzinga.com/files/images/story/2024/1727121629_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Expedia Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$148.00</td>
<td>-</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$137.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$134.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$140.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Expedia Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Expedia Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Expedia Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Expedia Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXPE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Expedia Group analyst ratings.</a>
<h2>All You Need to Know About Expedia Group</h2>
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2023 sales), air tickets (3%), rental cars, cruises, in-destination, and other (11%), and advertising revenue (6%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
<h3>A Deep Dive into Expedia Group's Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Expedia Group's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 5.96%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 10.85%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Expedia Group's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 43.4% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Expedia Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.52%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Expedia Group's debt-to-equity ratio stands notably higher than the industry average, reaching 7.37. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXPE

Assessing Expedia Group: Insights From 15 Financial Analysts

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) has outperformed the market over the past 5 years by 8.19% on an annualized basis producing an average annual return of 22.21%. Currently, AECOM has a market capitalization of $13.57 billion. 
Buying $1000 In ACM: If an investor had bought $1000 of ACM stock 5 years ago, it would be worth $2,714.42 today based on a price of $101.19 for ACM at the time of writing.
<h3>AECOM's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727121617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In AECOM 5 Years Ago Would Be Worth This Much Today

Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $84.3, a high estimate of $96.00, and a low estimate of $69.00. Marking an increase of 8.86%, the current average surpasses the previous average price target of $77.44. 
<img src="https://www.benzinga.com/files/images/story/2024/1727121616_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Sea by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sachin Salgaonkar</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jiong Shao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$69.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Ranjan Sharma</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Fawne Jiang</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Sachin Salgaonkar</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Alicia Yap</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Sachin Salgaonkar</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Sachin Mittal</td>
<td>DBS Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$75.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sea. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sea compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sea's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Sea's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sea analyst ratings.</a>
<h2>Discovering Sea: A Closer Look</h2>
Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value and number of transactions. Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce, which is now the main growth driver. Shopee is a hybrid C2C and B2C marketplace platform operating in eight core markets. Indonesia accounts for 35% of GMV, with the rest split mainly among Taiwan, Vietnam, Thailand, Malaysia, and the Philippines. For Garena, Free Fire was the most downloaded game in January 2022 and accounted for 74% of gaming revenue in 2021. Sea's third business, SeaMoney, provides lending and we foresee it becoming a larger part of the entire busines in the long term as its loan book has grown to $3.5 billion in 2024.
<h3>Key Indicators: Sea's Financial Health</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Sea showcased positive performance, achieving a revenue growth rate of 22.97% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.
Net Margin: Sea's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 2.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Sea's ROE excels beyond industry benchmarks, reaching 1.21%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.42%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Sea's debt-to-equity ratio is below the industry average. With a ratio of 0.62, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 10 Takes On Sea

Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) has outperformed the market over the past 20 years by 7.5% on an annualized basis producing an average annual return of 15.98%. Currently, Cintas has a market capitalization of $82.20 billion. 
Buying $100 In CTAS: If an investor had bought $100 of CTAS stock 20 years ago, it would be worth $1,921.09 today based on a price of $203.83 for CTAS at the time of writing.
<h3>Cintas's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727121612_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTAS

Here's How Much You Would Have Made Owning Cintas Stock In The Last 20 Years

<a href="https://patentcenter.uspto.gov/applications/17537110/ifw/docs">https://patentcenter.uspto.gov/applications/17537110/ifw/docs</a>
<figure class="image"><img src="https://pbs.twimg.com/media/GYL4nx-akAEpcwD?format=jpg&amp;name=small" alt="Image" /></figure><figure class="image"><img src="https://pbs.twimg.com/media/GYL4nyEakAQ2ba9?format=jpg&amp;name=small" alt="Image" /></figure>

Biotech

General

SNGX

Soligenix Will Be Issued U.S. Patent Number 12,097,291 Tomorrow Titled "Thermostable Vaccine Compositions And Methods Of Preparing Same"

Applied Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aplt#NASDAQ">APLT</a>) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
A company&#39;s changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
As such, the Zacks rating upgrade for Applied Therapeutics is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
<h2>Most Powerful Force Impacting Stock Prices</h2>
The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Applied Therapeutics imply an improvement in the company&#39;s underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
<h2>Harnessing the Power of Earnings Estimate Revisions</h2>
As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
<h2>Earnings Estimate Revisions for Applied Therapeutics</h2>
For the fiscal year ending December 2024, this company is expected to earn -$0.84 per share, which is a change of 40.9% from the year-ago reported number.
Analysts have been steadily raising their estimates for Applied Therapeutics. Over the past three months, the Zacks Consensus Estimate for the company has increased 18.6%.
<h2>Bottom Line</h2>
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
The upgrade of Applied Therapeutics to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
<a href="https://www.zacks.com/stock/news/2340046/all-you-need-to-know-about-applied-therapeutics-aplt-rating-upgrade-to-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2340046">To read this article on Zacks.com click here.</a>

Upgrades

APLT

All You Need to Know About Applied Therapeutics Rating Upgrade to Buy

BMO Capital Markets initiated coverage on OneStream Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>), an enterprise Finance <a target="_blank" href="https://www.benzinga.com/quote/OS" rel="noreferrer noopener">management platform provider</a>.
&#8220;We see OneStream positioned to gain share thanks to strength in data management, consolidation, and Artificial Intelligence/Machine Learning (AI/ML), which help differentiate it against a crowded field of both legacy and modern competitors, with broader ERP and financial application cloud migrations a tailwind.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/08/40447227/onestreams-ai-integration-expanding-cfo-platform-and-high-retention-rate-poised-to-fuel-strong-marke" rel="noreferrer noopener">OneStream&#8217;s AI Integration, Expanding CFO Platform, and High Retention Rate Poised to Fuel Strong Market Growth, Analysts Say</a>.
In a mixed landscape for &#8220;back-office&#8221; software spending, BMO Capital identifies a promising opportunity to exceed forecasts through new client acquisitions.
Additionally, recent discussions with several OneStream customers indicate significant potential to expand usage with new applications, which could maintain an NRR of around 110%. Together, these factors point to a compelling &#8220;beat and raise&#8221; scenario for both revenue and profit in the short term.
The analyst writes that the companies in the back-office sector are rapidly integrating new AI tools, but OneStream is already delivering value to its clients. Its Sensible ML product, while still in the early stages of adoption, is proving to be a powerful resource for enhancing business forecasting.
The analyst has initiated coverage on OneStream with an Outperform rating and <a target="_blank" href="https://www.benzinga.com/quote/OS/analyst-ratings" rel="noreferrer noopener">price target of $38</a>.
BMO Capital projects double-digit growth in the enterprise performance management software market, currently valued at around $7 billion. This growth is driven by the shift of ERP systems to the cloud, ongoing potential to capture market share from Excel-based workflows, and the opportunity to broaden use cases both within and outside the finance suite.
The analyst notes that the company&#8217;s estimate of a roughly $50 billion global market opportunity is credible, backed by their seat-based, bottom-up analysis. With less than 2% market share currently, this suggests a strong long-term growth potential, though the company will need to broaden its use cases over time steadily.
Price Action: OS stock is up 4.31% at $33.96 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40986267/ge-aerospace-takes-flight-with-ai-wingmate-boosts-innovation-employee-productivity-with-microsof" target="_blank" rel="noreferrer noopener">GE Aerospace Takes Flight With AI Wingmate: Boosts Innovation, Employee Productivity With Microsoft&#8217;s Azure AI</a>.</li>
</ul>

Analyst Color

Initiation

Strong Market Opportunities For OneStream Amid Rising Demand for AI-Driven Financial Solutions, Analyst Says

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Enveric Biosciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/envb-stock-quote/">ENVB</a>) stock&nbsp;is heading higher on Tuesday alongside heavy pre-market trading of the biotechnology company&rsquo;s shares.



This comes with more than 13 million shares of ENVB stock changing hands as of this writing. To put that in perspective, the company&rsquo;s daily average trading volume is about 583,000 shares. Investors will also note that its <a href="https://finance.yahoo.com/quote/ENVB/key-statistics/">float is only 7.68 million units</a>.



The heavy trading of ENVB stock today comes without any news from Enveric Biosciences. That includes a lack of press releases or filings. There also isn&rsquo;t any analyst news that would send the shares higher today.



What is worth keeping in mind is that ENVB is a penny stock. This comes from its prior closing price of 50 cents and market capitalization of only $3.961 million.



<h2>What That Means for ENVB Stock</h2>



Being a penny stock opens Enveric Biosciences&rsquo; shares up to volatility and manipulation. This could come from speculative traders, or retail and day traders pump up the stock.



No matter the case, it makes ENVB shares a risky investment right now. While the stock is currently up, it might not remain that way for long without a catalyst behind its rally.



ENVB stock is up 17.8% as of Tuesday morning. However, the stock was down 60.5% year-to-date when markets closed yesterday.



Investors will want to keep reading for more of the most recent stock market stories today!



We have all of the hottest stock market news that traders need to know about on Tuesday! That includes the biggest pre-market stock movers this morning and other hot news today. You can catch up on all of that by checking out the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-30th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Tuesday</a></li>



<li><a href="https://investorplace.com/2024/07/apple-releases-iphone-ai-preview-7-things-to-know/">Apple Releases iPhone AI Preview: 7 Things to Know</a></li>



<li><a href="https://investorplace.com/2024/07/nio-stock-alert-nio-declares-success-with-self-driving-chip/">NIO Stock Alert: Nio Declares Success with Self-Driving Chip</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-enveric-biosciences-envb-stock-up-18-today/">Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning!



Moving stocks this morning are earnings reports, clinical trial results and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Imunon (NASDAQ:<a href="https://investorplace.com/stock-quotes/imnn-stock-quote/">IMNN</a>) stock is rocketing more than 133% alongside <a href="https://finance.yahoo.com/news/imunon-report-topline-results-phase-200500840.html">Phase 2 clinical trial results</a>.</li>



<li>Jet AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/jtai-stock-quote/">JTAI</a>) shares are soaring over 57% despite a lack of news this morning.</li>



<li>Enveric Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/envb-stock-quote/">ENVB</a>) stock is surging more than 32% with strong early morning trading.</li>



<li>Inspirato (NASDAQ:<a href="https://investorplace.com/stock-quotes/ispo-stock-quote/">ISPO</a>) shares are rising close to 26% without any clear news this morning.</li>



<li>Pharming (NASDAQ:<a href="https://investorplace.com/stock-quotes/phar-stock-quote/">PHAR</a>) stock is heading over 21% higher ahead of its <a href="https://www.nasdaq.com/press-release/pharming-group-report-second-quarter-and-first-half-2024-financial-results-august-1-0">upcoming earnings report</a>.</li>



<li>Sprouts Farmers Market (NASDAQ:<a href="https://investorplace.com/stock-quotes/sfm-stock-quote/">SFM</a>) shares are increasing more than 17% after <a href="https://investorplace.com/earning-results/2024/07/sfm-stock-earnings-sprouts-farmers-market-for-q2-of-2024/?utm_source=barchart&amp;utm_medium=allother">releasing its Q2 earnings</a>.</li>



<li>Harmonic (NASDAQ:<a href="https://investorplace.com/stock-quotes/hlit-stock-quote/">HLIT</a>) stock is climbing over 17% with its <a href="https://www.nasdaq.com/press-release/harmonic-announces-second-quarter-2024-results-2024-07-29">Q2 earnings report</a>.</li>



<li>Davis Commodities (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtck-stock-quote/">DTCK</a>) shares are gaining more than 15% on Tuesday morning.</li>



<li>T2 Biosystems (NASDAQ:<a href="https://investorplace.com/stock-quotes/ttoo-stock-quote/">TTOO</a>) stock is getting an over 14% boost with its <a href="https://www.nasdaq.com/press-release/t2-biosystems-announces-second-quarter-2024-financial-results-2024-07-29">latest earnings report</a>.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) shares are up more than 14% after announcing <a href="https://www.nasdaq.com/press-release/investor-one-one-meeting-requests-open-29th-annual-enercom-denver-energy-investment">investor meeting plans</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>QXO (NASDAQ:<a href="https://investorplace.com/stock-quotes/qxo-stock-quote/">QXO</a>) stock is crashing over 80% after <a href="https://finance.yahoo.com/news/high-flying-qxo-erases-36-221350996.html">announcing a private placement</a>.</li>



<li>BIMI (NASDAQ:<a href="https://investorplace.com/stock-quotes/bimi-stock-quote/">BIMI</a>) shares are plummeting more than 23% on Tuesday morning.</li>



<li>Ekso Bionics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ekso-stock-quote/">EKSO</a>) stock is diving over 22% alongside its <a href="https://finance.yahoo.com/news/ekso-bionics-ekso-reports-q2-214505963.html">Q2 earnings results</a>.</li>



<li>Symbotic (NASDAQ:<a href="https://investorplace.com/stock-quotes/sym-stock-quote/">SYM</a>) shares are tumbling more than 18% after <a href="https://finance.yahoo.com/news/symbotic-inc-sym-reports-q3-213008077.html">reporting a Q3 loss</a>.</li>



<li>Lattice Semiconductor (NASDAQ:<a href="https://investorplace.com/stock-quotes/lscc-stock-quote/">LSCC</a>) stock is taking an almost 18% beating with its <a href="https://seekingalpha.com/article/4707817-lattice-semiconductor-corporation-lscc-q2-2024-earnings-call-transcript?source=feed_all_articles">latest earnings report</a>.</li>



<li>Lipella Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) shares are falling over 17% <a href="https://investorplace.com/2024/07/why-is-lipella-pharmaceuticals-lipo-stock-up-149-today/">after a rally yesterday</a>.</li>



<li>Cognition Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgtx-stock-quote/">CGTX</a>) stock is dropping more than 16% as it continues downward movement <a href="https://investorplace.com/2024/07/why-is-cognition-therapeutics-cgtx-stock-down-33-today/">on study results</a>.</li>



<li>NLS Pharmaceutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nlsp-stock-quote/">NLSP</a>) shares are sliding over 14% <a href="https://investorplace.com/2024/07/why-is-nls-pharmaceutics-nlsp-stock-up-48-today/">following a merger rally yesterday</a>.</li>



<li>Troops (NASDAQ:<a href="https://investorplace.com/stock-quotes/troo-stock-quote/">TROO</a>) stock is decreasing more than 13% today.</li>



<li>Loop Media (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) shares close out our pre-market stock movers down over 12% after <a href="https://www.stocktitan.net/news/LPTV/loop-media-inc-announces-new-partnership-and-nationwide-launch-of-u3mffuxudp5v.html">jumping yesterday on a new partnership</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-30th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ekso Bionics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ekso-stock-quote/">EKSO</a>) stock is taking a beating on Tuesday following the release of the exoskeleton company&rsquo;s <a href="https://finance.yahoo.com/news/ekso-bionics-reports-record-quarterly-200500459.html">Q2 earnings report</a>.



The bad news for Ekso Bionics starts with its diluted earnings per share of -13 cents. That&rsquo;s worse than the <a href="https://finance.yahoo.com/news/ekso-bionics-ekso-reports-q2-214505963.html">-11 cents per share</a> Wall Street was expecting. Even if it&rsquo;s an improvement over the company&rsquo;s -31 cents per share from the same period of the year prior.



Also not helping matters is Ekso Bionics&rsquo; revenue of $4.95 million for the quarter. Yet again, that&rsquo;s worse than the $5.17 million analysts were expecting from the company. Even if it&rsquo;s up 5% year-over-year from $4.7 million.



Ekso Bionics CEO Scott Davis said the following in the Q2 earnings report.




&ldquo;With the Medicare reimbursement mechanisms in place, we are focused on reaching a larger U.S. population of individuals living with a spinal cord injury (&ldquo;SCI&rdquo;) and anticipate increased demand for Ekso Indego Personal in the second half of the year and longer term.&rdquo;




<h2>How This Affects EKSO Stock</h2>



Ekso Bionics stock isn&rsquo;t seeing much trading activity this morning despite the lackluster earnings report. This has about 12,000 shares changing hands as of this writing. That&rsquo;s still well below its daily average trading volume of about 55,000 shares.



EKSO stock is down 15.2% as of Tuesday morning. The stock was also down 52.1% year-to-date when markets closed yesterday.



Investors seeking out more of the most recent stock market stories will want to stick around!



We have all of the hottest stock market news ready to go on Tuesday! A few examples include what&rsquo;s happening with shares of QXO&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/qxo-stock-quote/">QXO</a>) and Enveric Biosciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/envb-stock-quote/">ENVB</a>) stock, as well as the biggest pre-market stock movers this morning. All of that info is ready at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-qxo-qxo-stock-down-80-today/">Why Is QXO (QXO) Stock Down 80% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-enveric-biosciences-envb-stock-up-18-today/">Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-30th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Tuesday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-ekso-bionics-ekso-stock-down-15-today/">Why Is Ekso Bionics (EKSO) Stock Down 15% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Ekso Bionics (EKSO) Stock Down 15% Today?

Psychedelic drug developers face setback as ecstasy-based drug rejected by FDA

Medical journal retracts three articles related to MDMA for PTSD

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Enveric Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/envb-stock-quote/">ENVB</a>) just reported results for the second quarter of 2024.<ul><li>Enveric Biosciences reported earnings per share of -23 cents. This was above the analyst estimate for EPS of -55 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/envb-stock-earnings-enveric-biosciences-for-q2-of-2024/">ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024

Enveric Biosciences GAAP EPS of -$0.23

Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD

An update from Enveric Biosciences (ENVB) is now available. Enveric Biosciences, Inc. is set to unveil its Investor Presentation on their website o...

Enveric Biosciences Announces Upcoming Investor Presentation Release

Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report

ATAI

ATNF

CGTX

CMND

CMPS

CYBN

DRUG

DTCK

GHRS

LIPO

LPTV

MNMD

NLSP

SEEL

SPRC

TTOO

Press Releases

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

Enveric Biosciences to Participate in BIO International Convention 2024

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

Enveric Biosciences Announces Patent Granted for Drug Candidate

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Enveric Biosciences

Enveric Biosciences (ENVB) Forecast

Enveric Biosciences (NASDAQ:ENVB) Stock, Quote.Headers.trade-ideas